Group 1 - As of March 14, 66 companies have disclosed their 2023 distribution plans, with 13 companies including stock transfers in their plans [1] - The companies with the highest stock transfer ratios include Anfu Technology (10 shares for 4.5 shares), Te Yi Pharmaceutical (10 shares for 4 shares), and Senqilin (10 shares for 4 shares) [1] - All 13 companies that announced stock transfers also included cash dividends, while 53 companies opted for pure cash distribution [1] Group 2 - Among the companies that disclosed stock transfer plans, 13 have reported their annual or preliminary performance, with 11 showing a year-on-year increase in net profit [1] - The companies with the highest net profit growth include Dike Co., Fengshang Culture, and Haohai Biological, with increases of 2336.51%, 813.92%, and 130.58% respectively [1] - Two companies reported a decline in net profit, with the largest decreases seen in Demingli and Guangsha Huaneng, at 62.97% and 4.28% respectively [1] Group 3 - In terms of market performance, on the first day of the stock transfer announcement, 11 stocks rose while 2 fell, with Senqilin and Kangpu Chemical experiencing significant declines [2] - Since the announcement of the stock transfer plans, 10 stocks have increased in price, with the largest gains seen in Langhong Technology (17.76%) and George White (15.22%) [2] - Three stocks have decreased in price since the announcement, with Kangpu Chemical showing the largest cumulative decline of 4.56% [2]

Core Viewpoint - Haohai Biological Technology Co., Ltd. is currently trading at 54.9 yuan with a PE ratio of 30.90, which is significantly lower than the industry average of 56.56 [1][2] Company Summary - The main business of Haohai Biological includes the research, production, and sales of medical devices and pharmaceuticals, with key products such as ophthalmic viscoelastic devices, artificial lenses, and hyaluronic acid [1] - As of February 29, 2020, the number of shareholders increased to 7,605, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Financial Performance - In the first quarter of 2025, the company reported a revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.31 million yuan, down 7.41% year-on-year, with a gross margin of 69.52% [1] Industry Comparison - The average PE ratio for the medical device industry is 56.56, while the median is 39.76, positioning Haohai Biological at the 59th rank within the industry [1][2]

FF301 公司名稱: 上海昊海生物科技股份有限公司 (「本公司」)（於中華人民共和國註冊成立的股份有限公司） 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06826 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 39,141,840 | RMB | | 1 | RMB | | 39,141,840 | | 增加 / 減少 (-) | | | -612,600 | | | | RMB | | -612,600 | | 本月底結存 | | | 38,529,240 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海昊海生物科技股份有限公司 (「本公司」)（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06826 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 39,141,840 | RMB | | 1 | RMB | | 39,141,840 | | 增加 / 減少 (-) | | | -612,600 | | | | RMB | | -612,600 | | 本月底結存 | | | 38,529,240 ...

Industry Overview - The medical beauty industry in China has developed rapidly despite its late start, with a comprehensive industry chain that includes upstream raw material suppliers and medical equipment providers, midstream public and private institutions, and downstream consumers [1][2]. Key Players - Major upstream raw material manufacturers include Huaxi Biological, Aimeike, Haohai Biological, Huadong Pharmaceutical, and Jiao Dian Biological, while medical equipment is primarily supplied by foreign leading manufacturers [2]. - Midstream medical institutions consist of well-known entities such as Huahan Plastic Surgery, Lido Plastic Surgery, and Ruile Medical, along with emerging platforms like Xinyang and Gem [2]. Regional Distribution - The coastal regions of China have a dense distribution of representative enterprises in the medical beauty industry, with significant concentrations in Beijing, Shanghai, and Guangzhou, which are home to top research institutions and production companies [5]. - These regions attract numerous renowned medical beauty hospitals and clinics, providing comprehensive and high-quality services to consumers [5]. Business Layout of Representative Companies - Companies like Aimeike and Huaxi Biological focus on domestic sales, while others like Langzi and Huahan have diversified regional strategies across various provinces [7]. - Some companies specialize in product development, while others emphasize service delivery, with notable examples including Aimeike and Haohai focusing on product R&D, and Aoyuan Meigu's strong hospital brand image [7]. Financial Performance - Aimeike reported a medical beauty business revenue of 3.023 billion yuan, with a business proportion of 99.90%, indicating a strong focus on medical devices [8]. - Huadong Pharmaceutical generated 2.041 billion yuan from its medical beauty segment, accounting for 4.87% of its total business [9]. Investment Trends and Future Plans - Companies are actively expanding their business layouts with a trend towards diversification and internationalization, such as Aimeike's acquisition of a Korean company and Haohai's collaboration with a U.S. firm for product innovation [10][11]. - Huadong Pharmaceutical is expanding its medical beauty business through acquisitions and partnerships, while Huaxi Biological is investing in new technologies and products [10][11].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ■ 上述回购股份符合法律法规的规定及公司既定的回购股份方案。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股 份》等相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进 展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 公司A股2024年半年度权益分派实施完毕后，本次以集中竞价交易方式回购公司A股股份价格上限由不 超过89.71元/股（含），调整为不超过89.31元/股（含）。具体内容详见公司于2024年10月11日在上海 证券交易所网站（www.sse.com.cn）披露的《上海昊海生物科技股份有限公司关于2024年半年度权益分 派实施后调整回购A股股份价格上限的公告》（公告编号：2024-056）。 公司A股2024年年度权益分派实施完毕后，本次以集中竞价交易方式回购公司A股股份价格上限由不超 过89.31元/ ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688366 证券简称：昊海生科 公告编号：2025-036 上海昊海生物科技股份有限公司 关于第二期以集中竞价交易方式回购公司 A股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 上海昊海生物科技股份有限公司（以下简称"公司"）于2024年8月16日召开第五届董事会第二十五次会 议审议通过了《关于第二期以集中竞价交易方式回购公司A股股份方案的议案》，同意公司以集中竞价 交易方式回购公司A股股份，回购的A股股份拟用于员工持股计划或股权激励，回购资金总额不低于 10,000.00万元（含），不超过20,000.00万元（含），回购价格不超过89.71元/股，回购期限自董事会审 议通过回购股份方案之日起12个月内。具体内容详见公司于2024年8月17日在上海证券交易所网站 （www.sse.com.cn）披露的《上海昊海生物科技股份有限公司关于第二期以集中竞价交易方式回购公司 A股股份的方案暨回购报告书》（公 ...

Core Viewpoint - Haohai Biological Technology announced on the evening of August 1 that it will not implement the A-share share buyback in July 2025 [1] Group 1 - The company released an announcement regarding its decision on share buyback [1]

Core Viewpoint - Haohai Biological Technology (06826) announced that as of July 31, 2025, the company has not implemented an A-share buyback program, having repurchased a total of 1.8324 million A-shares, representing 0.79% of the total share capital of 233 million shares [1] Summary by Category - **Share Buyback Details** - The company repurchased 1.8324 million A-shares through centralized bidding [1] - This represents 0.79% of the total share capital of 233 million shares [1] - The highest transaction price was 63.58 yuan per share, while the lowest was 49.25 yuan per share [1] - The total amount spent on the buyback was 104 million yuan, excluding transaction fees [1]

Core Viewpoint - The company, Haohai Biological Technology (06826), announced that it has not implemented an A-share buyback as of July 2025, with a total of 1.8324 million A-shares repurchased, representing 0.79% of the total share capital of 233 million shares [1] Summary by Relevant Sections - **Share Buyback Details** - The company repurchased a total of 1.8324 million A-shares through centralized bidding, with a maximum transaction price of 63.58 CNY per share and a minimum transaction price of 49.25 CNY per share [1] - The total amount spent on the buyback was 104 million CNY, excluding transaction fees such as stamp duty and commission [1]